OptiNose (OPTN) Competitors

OptiNose (NASDAQ:OPTN) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.

Which has more volatility and risk, OPTN or ALLO?

OptiNose has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Does the media refer more to OPTN or ALLO?

In the previous week, OptiNose had 14 more articles in the media than Allogene Therapeutics. MarketBeat recorded 20 mentions for OptiNose and 6 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.13 beat OptiNose's score of 0.12 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptiNose	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, OPTN or ALLO?

OptiNose has higher revenue and earnings than Allogene Therapeutics. OptiNose is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptiNose	$75.67M	1.22	-$35.48M	-$4.20	-2.18
Allogene Therapeutics	$22K	15,060.41	-$327.27M	-$1.33	-1.15

Is OPTN or ALLO more profitable?

Allogene Therapeutics has a net margin of 0.00% compared to OptiNose's net margin of -41.16%. OptiNose's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptiNose	-41.16%	N/A	-27.42%
Allogene Therapeutics	N/A	-52.13%	-41.29%

Do analysts recommend OPTN or ALLO?

OptiNose presently has a consensus price target of $9.00, suggesting a potential downside of 1.53%. Allogene Therapeutics has a consensus price target of $9.29, suggesting a potential upside of 509.11%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than OptiNose.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptiNose	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allogene Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Do insiders & institutionals have more ownership in OPTN or ALLO?

85.6% of OptiNose shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 2.3% of OptiNose shares are held by insiders. Comparatively, 24.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor OPTN or ALLO?

Allogene Therapeutics received 35 more outperform votes than OptiNose when rated by MarketBeat users. Likewise, 65.89% of users gave Allogene Therapeutics an outperform vote while only 63.04% of users gave OptiNose an outperform vote.

Company	Underperform	Outperform
OptiNose	Outperform Votes 249 63.04%	Underperform Votes 146 36.96%
Allogene Therapeutics	Outperform Votes 284 65.89%	Underperform Votes 147 34.11%

Summary

Allogene Therapeutics beats OptiNose on 12 of the 18 factors compared between the two stocks.